DNA vaccines against influenza
Anna Stachyra, Anna Góra-Sochacka and Agnieszka Sirko
Genetic vaccine technology has been considerably developed within the last two decades. This cost effective and promising strategy can be applied for therapy of cancers and for curing allergy, chronic and infectious diseases, such as a seasonal and pandemic influenza. Despite numerous advantages, several limitations of this technology reduce its performance and can retard its commercial exploitation in humans and its veterinary applications. Inefficient delivery of the DNA vaccine into cells of immunized individuals results in low intracellular supply of suitable expression cassettes encoding an antigen, in its low expression level and, in turn, in reduced immune responses against the antigen. Improvement of DNA delivery into the host cells might significantly increase effectiveness of the DNA vaccine. A vast array of innovative methods and various experimental strategies have been applied in order to enhance the effectiveness of DNA vaccines. They include various strategies improving DNA delivery as well as expression and immunogenic potential of the proteins encoded by the DNA vaccines. Researchers focusing on DNA vaccines against influenza have applied many of these strategies. Recent examples of the most successful modern approaches are discussed in this review.
Acta Biochimica Polonica, 61(3), 515-522, Review
Acta Biochimica Polonica is indexed in: Current Contents, Biochem. and Biophys. Citation Index, BIOSIS, Chemical Abstracts, Excerpta Medica, Medline, Index Copernicus, CBR
Acta Biochimica Polonica is a member of the Committee on Publication Ethics (COPE)
Copyright © by Pawel Pomorski and Polish Biochemical Society 2009